Search:
Main Menu
Login | RSS |

BioPharmArena.com

News, Topics and Careers in Biopharmaceuticals and Biotechnology

Ardea To Present Data On HIV Non Nucleoside Reverse Transcriptase Inhibitor And Two MEK Inhibitors At Upcoming Medical Conferences

January 30th, 2008 by Barry - Admin BioPharmArena

Ardea Biosciences, Inc. (Nasdaq: RDEA) announced that data will be presented on its second generation non-nucleoside reverse transcriptase inhibitors (NNRTIs), at the 21st International Conference on Antiviral Research (ICAR). Additionally, data on two of the Company’s mitogen-activated ERK kinase (MEK) inhibitors, RDEA119 and RDEA436, will be presented at the American Association for Cancer Research (AACR) annual meeting.

The presentation details are as follows:

– 21st ICAR in Montreal, Quebec, Canada

Date/Time: Monday, April 14, 2008 at 4:00 p.m. Eastern Time
Title: A Novel NNRTI Class with Potent Anti-HIV Activity against
NNRTI-Resistant Viruses

Location: Poster Session 1 (Poster #80)

- AACR Annual Meeting in San Diego, California

Date/Time: Tuesday, April 15, 2008 at 1:00 p.m. Pacific Time
Title: RDEA119, a Potent and Highly Specific MEK Inhibitor is
Efficacious in Mouse Tumor Xenograft Studies
Location: Poster Session 32 (Poster #4878), Exhibit Hall B-F

Date/Time: Tuesday, April 15, 2008 at 1:00 p.m. Pacific Time
Title: RDEA436, a Novel MEK Inhibitor with Favorable
Pharmacokinetic Properties
Location: Poster Session 32 (Poster #4895), Exhibit Hall B-F

Posted in News, Research and Development, Clinical Research and Clincal Trials | No Comments »

Kidney Transplants Without Lifetime On Immunosuppressive Drugs In Sight

January 25th, 2008 by Barry - Admin BioPharmArena

The possibility of having a kidney transplant without spending a lifetime on immunosuppressive drugs has come a step or two closer with the announcement this week of two studies using two new techniques to discourage rejection of the donor organ.

The studies are published in today’s issue of the New England Journal of Medicine (NEJM), 24th January.

In the first study which was carried out by researchers at Massachusetts General Hospital and Harvard Medical School in Boston, five patients with end stage kidney disease received combined bone marrow and kidney transplants from relatives that did not match. This was done in three stages. First their immune system was partly inactivated, then they were given a bone marrow graft from the donor, and then they received the donor’s kidney.

 Read more …….

MedicalNewsToday.com

Posted in News, Clinical Research and Clincal Trials | No Comments »

Scientists Build First Man-Made Genome; Synthetic Life Comes Next

January 25th, 2008 by Barry - Admin BioPharmArena

By Alexis Madrigal

Scientists have built the first synthetic genome by stringing together 147 pages of letters representing the building blocks of DNA.

The researchers used yeast to stitch together four long strands of DNA into the genome of a bacterium called Mycoplasma genitalium. They said it’s more than an order of magnitude longer than any previous synthetic DNA creation. Leading synthetic biologists said with the new work, published Thursday in the journal Science, the first synthetic life could be just months away — if it hasn’t been created already.

“We consider this the second in our three-step process to create the first synthetic organism,” said J. Craig Venter, president of the J. Craig Venter Institute where scientists performed the study, on Thursday during a teleconference. “What remains now that we have this complete synthetic chromosome … is to boot this up in a cell.”

With the new ability to sequence a genome, scientists can begin to custom-design organisms, essentially creating biological robots that can produce from scratch chemicals humans can use. Biofuels like ethanol, for example.

“The J. Craig Venter Institute will be able to take a file stored on a computer and using synthetic chemistry, turn that information into life,” said Chris Voigt, a University of California at San Francisco synthetic biologist. “I would be shocked if it doesn’t come out in six months. I think they’ve done it.”

The technique is basically a reverse of the Human Genome Project, which translated DNA into the letters A, C, T and G, which represent the body’s building blocks: the nucleotides adenine, thymine, guanine and cytosine. Synthetic biologists’ ambitious goal is to arrange those letters to create never-before-seen organisms that will do their bidding.

The first phase of Venter’s three-step process, which he published last year, involved transplanting and “booting up” the genome of one species of bacterium into another. The remaining step is to combine the first two steps, then insert the new synthetic genome into a standard bacterium. Scientists said they expect the announcement of man-made life this year.

The ability to synthesize longer DNA strands for less money parallels the history of genetic sequencing, where the price of sequencing a human genome has dropped from hundreds of millions of dollars to about $10,000. Just a few years ago, synthesizing a piece of DNA with 5,000 rungs in its helix, known as base-pairs, was impossible. Venter’s new synthetic genome is 582,000 base-pairs.

“The largest piece that had been published in the scientific literature was 32 kilobases,” Venter said. “This is on the order of 20 times the size.”

“I would think that you could get to a million base pairs,” said Jim Collins, a professor of biomedical engineering at Boston University. “I don’t think there’s anything that’s hindering the use of these approaches to go for much bigger genomes.”

The key to the new technique is the yeast’s natural ability to staple long strands of DNA together.

“What’s really interesting about yeast is that … (it takes) multiple incomplete synthetic parts and assembles them,” said Daniel Gibson, a synthetic biologist at the Venter institute and senior author of the paper.

Hamilton Smith, a synthetic biologist who led the Venter Institute research, said that the team’s new technique should work for other genomes, although the full potential of the technique is unknown. But scientists were enthusiastic about the possibilities.

“Once this becomes routine, it allows us to build whatever genome we want,” Voigt said. “You can design a genome to incorporate a particular chemical process to change what the cells are eating and what the cells are making. You can make robotic cells.”

One goal of synthetic biology is to create a so-called minimal genome that would consist of the smallest amount of genes necessary to keep the organism alive. Such a bacterial “chassis” would provide an ideal platform for mounting modules like biofuel production to create tiny biological robots.

Other researchers, like Tom Knight of MIT, Drew Endy of Stanford, and a host of synthetic biology startup companies are all after this prize, which could lead to a replacement for fossil fuels. Voigt sits on the scientific advisory board of a biofuels startup, Amyris.

But synthetic biologists are also planning to scale up from the simplest organisms to the most complex: human beings. The first bacterial genome was sequenced in 1995 and was followed by the landmark sequencing of the human genome in 2001. Based on that trajectory, Voigt estimated that a synthetic human genome — which could be used in human cloning research — could be created by 2014.

But before researchers can do that level of synthetic biology, scientists will need to automate their methods. Beyond this work, Voigt said, scientists will need programming tools, in the same way computer scientists use higher level programming languages like Fortran, C++ and Java, to control computer function.

“(Otherwise it’s like) writing Vista in binary,” he said. “It’s just not going to happen.”

————————————

The article was first published on Wired Website.

Posted in News | No Comments »

Video - Staffing Challenges in Clinical Research

January 20th, 2008 by Barry - Admin BioPharmArena

Staffing Challenges in Clinical Research (6 minutes)

Video features Taren Grom, Editor of PharmaVOICE magazine talks with Micheal Hliniak, CEO of InVentiv Clinical, about staffing challenges in the outsourcing arena. Part of the PharmaVOICE Webcast Network.

Posted in Multimedia, Training for BioPharmaceutical Careers, Clinical Research and Clincal Trials | No Comments »

Resiniferatoxin And Botulinum Toxin Type A For Treatment Of Lower Urinary Tract Symptoms

January 14th, 2008 by Barry - Admin BioPharmArena

UroToday.com- Resiniferatoxin (RTX) and botulinum toxin type A (BTX-A) have drawn increasing attention in recent years as potential treatments for lower urinary tract symptoms (luts), including overactive bladder (OAB). RTX acts by desensitizing the transient receptor potential vanilloid type 1 (TRPV1) a non-specific Ca2+ channel previously known as vanilloid receptor. BTX-A is used in purified form as a medication for disorders involving involuntary muscle contractions including blepharospasm and strabismus. It acts by inhibiting the fusion of neurotransmitter-containing synaptic vesicles with the neuronal membrane an event essential for the release of neurotransmitters. It also reduces the release of glutamate and substance P from sensory neurons thus reducing the transmission of sensory input by these cells. Both drugs have been used in patients with bladder pain syndrome / interstitial cystitis. Cruz and Dinis from Porto, Portugal present an interesting review of the use of these compounds for the treatment of urinary disorders.

A role for intravesical RTX and BTX-A in the treatment of inflammatory bladder pain and frequency is strongly supported from data collected from animal models of chronic cystitis. Studies of RTX in humans for bladder pain syndrome are conflicting. A small randomized and placebo controlled trial of 18 patients showed good results at one month with no significant benefit at 3 months. A large pharmaceutical trial with 163 patients and several different doses of RTX compared to placebo showed no efficacy or even a potential signal of efficacy. For BTX-A, the results have also been contradictory in clinical trials. Not only is efficacy in question, but it carries risks of urinary retention that are not insignificant.

Read more ……

Medicalnewstoday.com

Posted in News, Global and Public Health, Clinical Research and Clincal Trials | No Comments »

Research Sheds Light On Previously Untreatable Lung Diseases

January 14th, 2008 by Barry - Admin BioPharmArena

Studies published in the Jan. 10 edition of the New England Journal of Medicine (NEJM) are providing clues into the treatment and diagnosis of LAM, or lymphangioleiomyomatosis, a progressive and deadly lung disease that affects women in their childbearing years. There currently are no treatments for LAM and scientists estimate as many as 250,000 women may be going misdiagnosed or undiagnosed.

Researchers from Cincinnati Children’s Hospital Medical Center and University of Cincinnati College of Medicine reported on a study testing the drug sirolimus in patients with LAM or tuberous sclerosis complex (TSC) with angiomyolipomas, benign kidney tumors common to both diseases. Approved to help transplant patients fight organ rejection, sirolimus treatment resulted in a 50 percent reduction in tumor growth; a significant improvement in lung function was observed in LAM patients. In addition, a letter published in the same issue of NEJM reports on preliminary data to support the use of a serum marker test to confirm a diagnosis of LAM. The disease has traditionally required a lung biopsy or CT scan for confirmation of diagnosis, contributing to diagnosis complications.

“These studies represent significant advances for LAM patients,” said Leslie Sullivan-Stacey, J.D., President and CEO of The LAM Foundation, a supporter of both studies. “The LAM Foundation has been the driving force behind major breakthroughs in LAM research over just the last decade, and we now have scientific evidence to support further study of treatments and diagnostic tools. The sirolimus study already is serving as the basis for other studies in TSC and LAM, including the first-ever LAM treatment trial, now enrolling patients.”

Read more ……

Medicalnewstoday.com

Posted in News, Global and Public Health, Research and Development | No Comments »

Emergent BioSolutions Announces That The Final Phase II Clinical Study Results For Typhoid Vaccine Reaffirms Clinical Endpoints Met

January 14th, 2008 by Barry - Admin BioPharmArena

Emergent BioSolutions Inc. (NYSE: EBS) announced that the final analysis from a recently completed, randomized, placebo-controlled, blinded Phase II clinical study reaffirmed that its single-dose, drinkable typhoid vaccine candidate was highly immunogenic and well-tolerated with an acceptable safety profile in the population studied. For the study, a total of 151 Vietnamese children between 5 and 14 years of age were enrolled. A total of 101 children received the vaccine candidate and 50 children received placebo. This clinical study is the first trial involving a pediatric population and was performed in collaboration with the Wellcome Trust, Oxford University and the Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam.

Study Results

- 97% of the children dosed developed an immune response, which was defined as an increase in Salmonella typhi LPS-specific IgG antibody levels and/or Salmonella typhi LPS-specific IgA antibody levels in the blood, suggestive of systemic and mucosal protective immunity, respectively. This represented a statistically significant difference from the placebo group.

- 93% of the children developed responses as measured by increases in Salmonella typhi LPS-specific IgG antibody levels suggestive of systemic protective immunity and 94% developed an immune response as measured by increase in Salmonella typhi LPS-specific IgA antibody levels suggestive of mucosal protective immunity.

- There were no safety concerns following administration of a single dose of the drinkable typhoid vaccine candidate. The proportion of subjects reporting adverse events was similar for the vaccinated group (26%) and placebo group (22%); this difference was not statistically significant.

- There were no serious adverse events reported, no deaths and no subjects withdrew due to adverse events. There were small differences in specific adverse events with more gastrointestinal symptoms and headaches reported in the vaccinated group and more respiratory symptoms in the placebo group.

Read more ……

Medicalnewstoday.com

Posted in News, Global and Public Health, Clinical Research and Clincal Trials | No Comments »

Results Of Clinical Trial Of Experimental Weight-Loss Drug

January 14th, 2008 by Barry - Admin BioPharmArena

The first clinical studies of an experimental drug have revealed that obese people who take it for 12 weeks lose weight, even at very low doses. Short-term studies also suggest that the drug, called taranabant - the second drug designed to fight obesity by blocking cannabinoid receptors in the brain - causes people to consume fewer calories and burn more, researchers report in the January issue of Cell Metabolism, a publication of Cell Press. Cannabinoid receptors are responsible for the psychological effects of marijuana (Cannabis sativa), and natural “endocannabinoids” are important regulators of energy balance.

“The effects of marijuana on appetite have been known for millennia from its medicinal and recreational use,” said study author Steven Heymsfield of Merck Research Laboratories. “The ingredient responsible stimulates cannabinoid receptors. When you block the cannabinoid system with an antagonist like taranabant, you suppress appetite.” However, the drug, developed by Merck, also comes with an increased risk of adverse side effects at higher doses, the study shows, including mild to moderate gastrointestinal and psychiatric effects.

The first proof of concept that so-called cannabinoid 1 receptor (CB1R) inverse agonists might offer an obesity therapy came from studies of another drug, developed by Sanofi-Aventis, called rimonabant. That drug is now in use for weight loss in several European countries as an adjunct to diet and exercise but has not received FDA approval for use in the United States.

Read more ……

Medicalnewstoday.com

Posted in News, Research and Development, Clinical Research and Clincal Trials | No Comments »

More Informative Picture Of Cancer Survival Shown Using New Statistical Technique

January 14th, 2008 by Barry - Admin BioPharmArena

Researchers have developed a new method for presenting clinical trial survival data that includes data from all trial participants unlike the standard method, according to a commentary published online January 8 in the Journal of the National Cancer Institute.

In clinical studies, “time-to-event” data represents the time from the start of a study to an event, such as disease recurrence or death. But often many participants in a study do not experience an event before the study is over, so their survival time is not known. To overcome this data gap, the standard statistical method for presenting time-to-event results, known as the Kaplan-Meier survival curve, involves plotting the proportion of individuals surviving without an event over the period of the study. Using this method, researchers get an estimate of the median survival times. However, these plots also tend to make differences in survival between groups visually appear larger than they actually are.

To address this problem, Patrick Royston, D.Sc., of the Medical Research Council Clinical Trials Unit in London and colleagues developed a new method for plotting survival as a bar graph and tested it on data from a kidney cancer trial. In cases where a participant had not experienced an event, the researchers estimated that person’s survival by using their prognosis and length of time in the trial.

Read more ……

Medicalnewstoday.com

Posted in Clinical Data Management, News, Technologies in the BioPharmaceutical Industry, Clinical Research and Clincal Trials | No Comments »

Seeking Funding For Cancer Vaccine Clinical Trial And Fast Track Commercialization

January 14th, 2008 by Barry - Admin BioPharmArena

BIOVEN, a biotechnology company specializing in therapeutic vaccines for cancer, is targeting to raise US$16million to fund its clinical trials and fast track the commercialization of its three breakthrough therapeutic cancer vaccine products and a therapeutic hepatitis B vaccine.

The company secured ownership and rights to market the Cuban technology globally for US$32 million.

“We are looking for investors to come into the project,” said Chairman Mukhriz Mahathir. He said that the funds raised will be used for Phase II and III clinical trials for its EGF cancer vaccine and hepatitis B therapeutic vaccine in Asian and European sites. The monies will also be used for listing the company in 2 years time.

The company has embarked on Phase II/III clinical trials on the breakthrough cancer vaccine products, the most developed of which is the Epidermal Growth Factor (EGF) cancer vaccine on terminally ill, late stage non-small cell lung cancer (NSCLC) patients.

The head of the project, Dr Gisela Gonzalez Marinello, notes that the EGF is not a prophylactic vaccine but fights the regeneration of carcinogenic cells. It is injected once a month as a complement to traditional treatments such as chemotherapy and radiotherapy.

Read more ……

Medicalnewstoday.com

Posted in News, Clinical Research and Clincal Trials | No Comments »

Surface Logix Achieves Objectives With SLx-2101 In Phase 2a Clinical Trial In Hypertension

January 14th, 2008 by Barry - Admin BioPharmArena

Surface Logix announced positive results in the Company’s Phase 2a clinical trial of SLx-2101 in hypertension. The randomized, double-blind, placebo-controlled crossover Phase 2a study in 60 patients with uncontrolled hypertension demonstrated that SLx-2101 caused clinically significant reductions in blood pressure and was well tolerated. The trial was designed to examine the safety, tolerability and effect on blood pressure in patients of repeat oral doses of SLx-2101 once daily for up to 14 days.

“These data confirm the promise of efficacy seen in earlier clinical trials, and we plan to initiate a Phase 2b study of SLx-2101 in hypertension in the third quarter of 2008,” said Jim Mahoney, President and CEO of Surface Logix. “We believe that with our demonstrated 24-hour coverage from once daily dosing and excellent tolerability profile, we will be able to uniquely position SLx-2101 in several segments of the hypertension market.”

SLx-2101 is an oral, potent, selective, fast-onset, long-acting PDE5 inhibitor. Other PDE5 inhibitors have traditionally been used to treat erectile dysfunction (ED). SLx-2101 was designed specifically to expand the therapeutic potential of PDE5 inhibition beyond ED into larger cardiovascular markets such as hypertension. SLx-2101 is uniquely positioned among the known PDE5 inhibitors to address cardiovascular disease because, compared to currently marketed PDE5 drugs, SLx-2101 preferentially distributes into cardiovascular tissue. With its large volume of distribution, SLx-2101 achieves sustained plasma levels and a long duration of action, without showing accumulation upon repeat dosing. This allows for daily or on demand dosing with a predictable response in a number of cardiovascular disorders that currently marketed PDE5 therapies cannot adequately address.

Read more ……

Medicalnewstoday.com

Posted in News, Clinical Research and Clincal Trials | No Comments »

FDA Approves Cialis(R) (tadalafil) For Once Daily Use For The Treatment Of Erectile Dysfunction

January 14th, 2008 by Barry - Admin BioPharmArena

Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved Cialis(R) (tadalafil)(1) for once daily use (2.5 mg and 5 mg), an oral medication taken once per day to treat erectile dysfunction (ED). When Cialis for once daily use is taken daily, men can attempt sexual activity at anytime between doses.

Currently available in parts of Europe, this low-dose daily treatment option of Cialis may be most appropriate for men with ED who anticipate more frequent sexual activity (e.g. twice weekly). For other men, Cialis taken as needed - the previously approved dosing regimen - may be most appropriate.

In clinical trials, when taken without restrictions on the timing of sexual activity, Cialis for once daily use improved erectile function over the course of therapy.

“ED can be a chronic condition like diabetes or high blood pressure,” said Ridwan Shabsigh, M.D., Director of the Division of Urology at Maimonides Medical Center in New York. “As a urologist, I know couples like to have choices and will appreciate the availability of Cialis for once daily use.”

Cialis for use as needed transformed the U.S. ED market when it was approved in 2003 as the first and only PDE5 inhibitor clinically proven to provide sustained efficacy for up to 36 hours. Cialis for once daily use provides a new option for men who may be looking for a dosing option that can be taken without regard to timing of sexual activity. In consultation with their physician, patients now have the freedom to choose the dosing regimen that is appropriate for them.

Read more ……

Medicalnewstoday.com

Posted in News, Medical Doctors in Clinical Research, Clinical Research and Clincal Trials | No Comments »

Hawaii Biotech Receives Allowance To Perform West Nile Vaccine Clinical Tria

January 14th, 2008 by Barry - Admin BioPharmArena

Hawaii Biotech, Inc. announced that it has been notified by the United States Food and Drug Administration (FDA) that it may proceed to initiate a 24 patient safety study in healthy human volunteers with its recombinant, subunit West Nile vaccine. The trial will be conducted at a single site in Hawaii, which the company currently expects to start in April 2008, pending successful completion of financing sufficient funding to complete the trial. Depending on the actual start date, results of the trial may be available by the end of 2008.

HBI develops subunit vaccine candidates that have been shown to elicit protective immune responses in animal efficacy models for diseases such as West Nile, dengue, influenza, Ebola, malaria and tick-borne encephalitis.

“The West Nile vaccine will be the first candidate to enter clinical trials for Hawaii Biotech. This is a substantial milestone for the company as it is a novel vaccine candidate with which the FDA has had little experience. Receiving this notification from the FDA that we may proceed to human clinical trials is the first step in proving our technology in a clinical setting and to the scientific community,” said Dr. Carolyn Weeks-Levy, President and CEO of HBI.

Currently there is no vaccine for the prevention of West Nile disease in humans; a disease that has caused over 25,000 cases of disease and over 1000 deaths since the virus was introduced in the U.S. in 1999.

Read more ……

Medicalnewstoday.com

Posted in News, Clinical Research and Clincal Trials | No Comments »

New Drug Application For Alogliptin (syr-322) In The US Submitted By Takeda

January 14th, 2008 by Barry - Admin BioPharmArena

Takeda Pharmaceutical Company Limited (Takeda) has announced that Takeda Global Research & Development Center, Inc. submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for alogliptin (development code: SYR-322), a highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes. Discovered by Takeda San Diego, Inc., alogliptin was designed to selectively inhibit DPP-4 taken orally once daily.

DPP-4 inhibitors are a new class of oral agents for the treatment of type 2 diabetes, which slow the inactivation of incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). The incretins play a major role in regulating blood glucose levels and may have the potential to improve pancreatic beta-cell function.

The NDA submission was supported by six Phase 3 clinical trials involving over 2,000 patients conducted in 220 centers worldwide. The safety and efficacy of alogliptin was studied as a once-daily monotherapy adjunct to diet and exercise and as an add-on therapy to other antidiabetic medications including sulfonylureas, metformin, thiazolidinediones (TZDs), and insulin. In the studies, alogliptin was associated with statistically significant reductions in hemoglobin A1c, which reflects average blood glucose concentration over the previous two to three months. Alogliptin was generally well-tolerated and weight neutral. There was no increase in hypoglycemia compared to placebo.

Read more ……

Medicalnewstoday.com

Posted in News, Clinical Research and Clincal Trials | No Comments »

NicOx Announces Pfizer Initiates Phase 2 Clinical Development For PF-03187207 In Japan

January 14th, 2008 by Barry - Admin BioPharmArena

NicOx S.A. (Euronext Paris: COX) announced that Pfizer Inc (NYSE: PFE) has initiated a dose-ranging phase 2 clinical study for PF-03187207 in Japan. PF-03187207 is a new experimental medicine for the treatment of glaucoma, which is currently in an ongoing phase 2 proof-of-concept study in the United States (see press releases of March 28 and 29, 2007). Glaucoma and ocular hypertension are a group of severe eye diseases that can lead to blindness and this new Japanese study will compare the safety and efficacy of PF-03187207 to Xalatan(R) (latanoprost) in Japanese patients with these conditions. Xalatan(R) is a proprietary Pfizer product and the leader in worldwide glaucoma sales, with approximately $1.5 billion of franchise sales in 2006.

PF-03187207 is the lead development compound generated under the August 2004 collaboration agreement between Pfizer and NicOx, which focuses on the research and development of nitric oxide-donating prostaglandin F2-alpha analogs for the treatment of glaucoma (see NOTE).

Maarten Beekman, Vice President of Clinical Development at NicOx, said: “We believe the initiation of this separate Japanese study for PF-03187207 highlights Pfizer’s determination to rapidly advance this clinical program towards coordinated regulatory filing in the world’s major pharmaceutical markets. Preclinical results have suggested that NicOx’ technology has the potential to deliver improved treatments for glaucoma and we look forward to the results of the ongoing proof-of-concept phase 2 study for PF-03187207 in the United States.”

Read more ……

Medicalnewstoday.com

Posted in News, Clinical Research and Clincal Trials | No Comments »

Clinical Trial Of HCV Treatment Proves Cost-Effective

January 14th, 2008 by Barry - Admin BioPharmArena

Two new randomized controlled trials show that treating Hepatitis C (HCV) with peginterferon and ribavirin for shorter durations can yield success rates similar to those from longer treatment lengths, with cost-savings and lower risk of serious side effects. Patients’ HCV-RNA levels after 4 weeks of treatment may be an important factor for determining the best treatment length. These findings are in the January issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD). The articles are also available online at Wiley Interscience.

HCV genotype is the single most important predictor of a patient’s outcome after treatment with peginterferon and ribavirin. Only about half of all patients with genotype 1 will achieve a sustained viral response, compared to 70 to 90 percent of patients with genotype 2 or 3. Regardless of HCV genotype, patients who respond quickly to the drugs are also more likely to be cured by them. Based on these differences, and because the therapy is costly and carries risks of serious side effects, researchers have been exploring ways to customize treatment for each patient.

Researchers led by Alessandra Mangia of Italy’s Istituto di Ricovero e Cura a Carattere Scientifico, Casa Sollievo Della Sofferenza, in San Giovanni Rotondo conducted a randomized controlled trial of patients with HCV genotype 1. They hypothesized that variable treatment duration based on the first measurement of undetectable HCV RNA would be as effective as standard 48-week treatment. They enrolled 696 patients, 237 of whom received standard HCV. The remaining 459 were treated for 24, 48, or 72 weeks, if HCV-RNA was undetectable at 4, 8, or 12 weeks, respectively.

Read more ……

Medicalnewstoday.com

Posted in News, Clinical Research and Clincal Trials | No Comments »

Ardea Biosciences’ Lead NNRTI For HIV, RDEA806, To Enter Phase 2a Proof-of- Concept Clinical Trial

January 14th, 2008 by Barry - Admin BioPharmArena

Ardea Biosciences, Inc. (Nasdaq: RDEA) announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom has authorized a Phase 2a clinical trial evaluating RDEA806, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), in patients with human immunodeficiency virus (HIV), the causative agent of AIDS.

“There is a clear unmet need for new NNRTIs that have the potential for a lower incidence of neuropsychiatric adverse effects, a high barrier to resistance, activity against resistant strains and the ability to be combined with other therapeutic agents,” said Barry Quart, PharmD, President and CEO of Ardea Biosciences. “We believe that RDEA806 has the potential to offer a new option for patients with HIV and are excited to move this novel compound into Phase 2 clinical testing. We expect to obtain results from this trial in the first quarter of 2008.”

The Phase 2a randomized, double-blind, proof-of-concept trial will be conducted in multiple European academic medical centers. The trial will evaluate the antiviral activity, pharmacokinetics, safety and tolerability of once daily and twice daily dose regimens of RDEA806 versus placebo in HIV-1 positive patients who are naive to antiretroviral treatment. The primary efficacy endpoint is the change from baseline in plasma viral load.

Read more ……

Medicalnewstoday.com

Posted in News, Clinical Research and Clincal Trials | No Comments »

Cephalon Submits New Drug Application For TREANDA For The Treatment Of Patients With Relapsed Indolent Non Hodgkin’s Lymphoma

January 14th, 2008 by Barry - Admin BioPharmArena

Cephalon, Inc. (Nasdaq: CEPH) announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting approval of TREANDA(R) (bendamustine HCl) for Injection for the treatment of patients with indolent B-cell non-Hodgkin’s lymphoma (NHL) who have progressed during or following treatment with rituximab or a rituximab-containing regimen. According to the National Cancer Institute, an estimated 30,000 people in the United States will be diagnosed in 2007 with indolent NHL, a serious and slow growing cancer of the lymphatic system that is difficult to treat because patients are prone to relapse after treatment.

“TREANDA is the lead product in our oncology pipeline and with this second NDA submission for the product in 2007 we have achieved a significant milestone for our business,” said Dr. Lesley Russell, Executive Vice President, Worldwide Medical and Regulatory Operations. “The clinical data supporting this submission highlight the potential of TREANDA to make a meaningful difference for patients with indolent NHL who have relapsed during or following treatment with rituximab.”

The TREANDA NDA for relapsed indolent NHL is supported by three studies in patients with NHL, including one in combination with rituximab. In these studies, patients treated with TREANDA had a high rate of response and a manageable and tolerable side effect profile, with adverse events similar to those observed with other chemotherapy agents.

Read more ……

Medicalnewstoday.com

Posted in News, Clinical Research and Clincal Trials | No Comments »